Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.4.2447

Inhibition by Imatinib of Expression of O-glycan-related Glycosyltransferases and Tumor-associated Carbohydrate Antigens in the K562 Human Leukemia Cell Line  

Sun, Qi-Chang (Department of Biochemistry and Molecular Biology, Medical College of Soochow University)
Liu, Mi-Bo (Department of Biochemistry and Molecular Biology, Medical College of Soochow University)
Shen, Hong-Jie (The First Affiliated Hospital of Soochow University)
Jiang, Zhi (Department of Biochemistry and Molecular Biology, Medical College of Soochow University)
Xu, Lan (Department of Biochemistry and Molecular Biology, Medical College of Soochow University)
Gao, Li-Ping (Department of Biochemistry and Molecular Biology, Medical College of Soochow University)
Ni, Jian-Long (Department of Biochemistry and Molecular Biology, Medical College of Soochow University)
Wu, Shi-Liang (Department of Biochemistry and Molecular Biology, Medical College of Soochow University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.4, 2013 , pp. 2447-2451 More about this Journal
Abstract
Objective: To study changes of tumor associated carbohydrate antigen (TACAs) expression and mRNA levels for tumor associated glycosyltransferases, and assess subcellular localizations of N-acetyl galactosyltransferases (GalNAc-Ts) in the K562 leukemia cell line after imatinib treatment. Methods: RT-PCR was performed to analyze the expression of glycosyltransferases which synthesize O-glycan in tumor-associated carbohydrate antigens (TCTAs). The expression of Tn antigen, T antigen and sialyl T antigen on K562 cell membranes was measured by flow cytometry after treatment with different concentrations of imatinib. Co-localization of GalNAc-Ts and ER (endoplasmic reticulum) was determined by confocal laser scanning microcopy. Results: Transcript expression levels of several glycosyltransferases related to TCTAs were decreased after imatinib ($0-0.3{\mu}M$) treatment. Expression of Tn antigen and T antigen was increased while that of sialyl T antigen was decreased. Co-localization of GalNAc-Ts and ER was reduced by $0.2{\mu}M$ of imatinib. Conclusion: Imatinib inhibited the expression of O-glycan related TACAs and several related glycosyltransferases, while decreasing the co-localization of GalNAc-Ts and ER and normalizing O-glycosylation in the K562 human leukemia cell.
Keywords
Imatinib; K562; glycosyltransferases; tumor-associated carbohydrate antigens; leukemia cells;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Boggon TJ, Eck MJ (2004). Structure and regulation of Src family kinases. Oncogene, 23, 7918-27.   DOI   ScienceOn
2 Brockhausen I (2006). Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep, 7, 599-604.   DOI   ScienceOn
3 Brockhausen I, Dowler T, Paulsen H (2009). Site directed processing: Role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2. Biochim Biophysica Acta, 1790, 1244-57.   DOI   ScienceOn
4 Buchdunger E, Zimmermann J, Mett H, et al (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 56, 100 4.
5 Danhauser-Riedl S, Warmuth M, Druker BJ, et al (1996). Activation of Src kinases p53/56lyn and p59hck by p210bcr/ abl in myeloid cells. Cancer Res, 56, 3589-96.
6 Deininger MWN, Goldman JM, Lydon N, Melo JV (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCRABL-positive cells. Blood, 90, 3691-8.
7 Faderl S, Talpaz M, Estrov Z, Kantarjian HM (1999). Chronic myelogenous leukemia: biology and therapygh. Ann Int Med, 131, 207 19.
8 Gerken TA, Owens CL, Pasumarthy M (1998). Site-specific core 1 O-glycosylation pattern of the porcine submaxillary gland mucin tandem repeat Evidence for the modulation of glycan length by peptide sequence. J Biol Chem, 273, 26580-8.   DOI
9 Gill DJ, Chia J, Senewiratne J, et al (2010). Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J Cell Biol, 189, 843-58.   DOI   ScienceOn
10 Hakomori S (1985). Aberrant glycosylation in cell membranes as focused on glycolipids:overview and perspectives. Cancer Res, 45, 2405-14.
11 Hakomori S (1996). Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res, 56, 5309-18.
12 Heimburg-Molinaro J, Lum M, Vijay G, et al (2011). Cancer vaccines and carbohydrate epitopes. Vaccine, 29, 8802-26.   DOI   ScienceOn
13 Hitomi T, Seiichi T, Michiie S, et al (2003). Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. Glycobiology, 13, 521-7   DOI   ScienceOn
14 Lionberger JM, Wilson MB, Smithgall TE (2000). Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem, 275, 18581-5.   DOI   ScienceOn
15 Reis CA, Osorio H, Silva L, et al (2010). Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol, 63, 322-9.   DOI   ScienceOn
16 Liu C, Lin D, Xu L, et al (2011). An anti-human ppGalNAcT-2 monoclonal antibody. Hybridoma, 30, 549-54.   DOI   ScienceOn
17 Lozzio CB, Lozzio BB (1975). Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome, Blood, 45, 321-34.
18 Quint s-Cardama A, Cortes J (2009). Molecular biology of bcr-abl1 positive chronic myeloid leukemia. Blood, 113, 1619-30.   DOI   ScienceOn
19 Warmuth M, Bergmann M, Priess A, et al (1997). The Src family kinase Hck interactswith Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem, 272, 33260-70.   DOI   ScienceOn
20 Yamada K, Mitsui Y, Kakoi N, et al (2012). One-pot characterization of cancer cells by the analysis of mucintype glycans and glycosaminoglycan. Anal Biochem, 421, 595-606.   DOI   ScienceOn